CEL-SCI Corporation (NYSEMKT:CVM) is lower after it said Tuesday that it has priced a "best efforts" underwritten public offering of common stock and warrants at a combined price of $0.76 for aggregate gross proceeds of $6 million, prior to deducting underwriting commissions and offering expenses and excluding the exercise of any warrants. Shares of the research and development company are down 17.89% at $0.70, with a 52-week range of $0.53 - $1.90.CEL-SCI Corporation (NYSEMKT:CVM) said that for every four shares sold, it will issue to investors in this offering one warrant to purchase a share of common stock. The warrants are immediately exercisable, expire Oct. 11, 2018, have an exercise price of $1.25 and trade on the NYSE MKT under the symbol "CVM WS". The offering is expected to close on or about Oct. 24, 2014, subject to the satisfaction of customary closing conditions. CVM intends to use the net proceeds of the offering for its Phase III clinical trial, other research and development, and general and administrative expenses.Illumina, Inc. (NASDAQ:ILMN), the life-science company late Monday reported better-than-expected Q3 results and Janney Capital Markets responded with an upgrade of its investment rating on the stock to buy from hold. Janney also boosted its price target on the stock to $192 from $165. The new price target is 17% above the stock's Monday closing price. Illumina, Inc. (NASDAQ:ILMN) is trading within a 52-week range of $80.88 to $185.00. In making the upgrade and price-target boost, Janney noted to clients that "Illumina beat expectations in 3Q and private sector sequencing adoption continues to exceed expectations."The firm said its checks indicate that ILMN's next-generation sequencing competition "remains sidelined with competition focused on diagnostics." It added: "Illumina continues to gain market-share in clinical and applied end-markets. Molecular diagnostic and service based competition is building, but we believe that ILMN will maintain growth due to its dominance in on the NGS instrument market and industry collaborations."RLJ Lodging Trust (NYSE:RLJ), a real-estate investment trust, said Tuesday it completed a $143.0 million secured financing with Wells Fargo. The company originated four separate first mortgage loans totaling $143.0 million. The base term for the loans is three years with four one-year extension options. Including extensions, this tranche of debt will mature in 2021. The mortgages are interest only for the first five years and bear a floating rate of LIBOR plus 225 basis points.Proceeds from the new mortgage loans retired five mortgage loans and reduced this tranche of debt's interest rate by 135 basis points, excluding the impact of a potential hedge. In addition to reducing interest rates, the company also further staggered its debt maturities and unencumbered one additional property. The company's unencumbered asset pool now consists of 117 assets, which represents a total of more than 70% of the company's 2013 pro forma Hotel EBITDA. RLJ Lodging Trust (NYSE:RLJ) shares were up 1.5% at $30.32 recently. Over the past 52 weeks, the stock has traded between $22.60 and $30.64.
Discover Hidden Gems
Don't miss the next big opportunity. Subscribe for timely alerts on potential market movers.
